Diabetes

Aescin is the active saponin from horse chestnut seed (Aesculus hippocastanum) and is one of the best-evidenced herbal treatments for chronic venous insufficiency (CVI), a condition closely associated with varicose veins. A Cochrane review of 17 RCTs (n=1,580) found it reduced leg pain and ankle swelling comparably to compression stockings. Germany's Commission E approved it for CVI symptoms. It acts by increasing venous tone, reducing capillary permeability, and inhibiting proteolytic enzymes that damage vessel walls.

Anthocyanosides are the flavonoid glycosides found in bilberry, blueberry, and other berries that have vasoactive and vasoprotective properties relevant to varicose veins. They stabilize collagen in vessel walls, reduce capillary permeability and fragility, and have demonstrated vasoactive properties in research (Bell & Gochenaur, J Appl Physiol 2006). They are the basis for bilberry's traditional and modern recommendation for venous insufficiency and varicose vein-related conditions.

The German Commission E and EMA monograph both list superficial phlebitis (inflamed superficial veins) as an approved indication for topical arnica. A randomized, double-blind, placebo-controlled pilot study in 60 patients post-varicose vein surgery found a trend toward reduced hematoma and pain, though results did not reach statistical significance. Traditional use for varicose veins and phlebitis is well documented.

Asiaticoside is a principal triterpenoid glycoside from Centella asiatica and a key active constituent in clinical trials showing benefit for CVI and varicose vein-associated microcirculatory dysfunction. It reduces endothelial permeability, stimulates collagen synthesis to strengthen vessel walls, and has been shown to normalize mucopolysaccharide metabolism in varicose vein patients. It is a component of the total triterpenic fraction (TTFCA) used in RCTs for CVI.

Bilberry (Vaccinium myrtillus) contains anthocyanosides and proanthocyanidins that, due to their similarity to OPCs from grape seed and pine bark, have been recommended for varicose veins. Its anthocyanosides have demonstrated vasoactive and vasoprotective properties (Bell & Gochenaur 2006) and collagen-stabilizing actions relevant to vessel wall integrity. It is included in EBSCO's evidence summary for varicose vein–associated conditions, though robust dedicated CVI clinical trials are limited.

Butcher's Broom (Ruscus aculeatus) root extract, containing the steroidal saponins ruscogenin and neoruscogenin, is approved by Germany's Commission E and recognized by the EMA for symptomatic treatment of CVI, a condition closely linked to varicose veins. Multiple clinical studies, including placebo-controlled trials and a meta-analysis, show reductions in leg edema and CVI symptoms. Most robust evidence uses it in combination (with hesperidin and vitamin C). The EMA monograph supports its use for heaviness, pain, and swelling in the legs associated with venous insufficiency.

Centella asiatica is the botanical source of Gotu Kola and has direct clinical trial evidence for CVI and varicose vein-related symptoms. A 2013 systematic review (PMC3594936) of eight RCTs found the plant's total triterpenic fraction improves microcirculatory parameters, reduces ankle edema, and relieves leg heaviness and pain. Dose-dependent reductions in capillary filtration and ankle circumference have been demonstrated in placebo-controlled trials.

Centella triterpenes—principally asiaticoside, madecassoside, asiatic acid, and madecassic acid from Centella asiatica—are the active constituents responsible for the plant's clinical effects in chronic venous insufficiency and varicose veins. Multiple placebo-controlled RCTs using the total triterpenic fraction (TTFCA) have demonstrated reductions in capillary filtration, ankle edema, and CVI symptom scores. These compounds reduce capillary permeability, stimulate collagen synthesis, and improve venous tone.

Diosmin is a naturally occurring flavonoid glycoside used as a venoactive drug for chronic venous disease (CVD), including varicose veins. A 2016 review and meta-analysis of RCTs found it significantly reduced leg and ankle swelling and lower leg pain. A 2012 review of 10 studies found moderate evidence for improving CVD symptoms including varicose veins, edema, and quality of life. The standard dose is 600 mg/day; it is widely prescribed in Europe for CVD.

Gotu Kola (Centella asiatica) has clinical evidence from multiple RCTs supporting its use for chronic venous insufficiency (CVI) and varicose vein-associated symptoms. A 2013 systematic review of eight RCTs concluded the herb likely improves CVI signs and symptoms. Its triterpenoid constituents (asiaticoside, madecassoside) improve microcirculation, reduce capillary permeability, and enhance venous tone. ConsumerLab notes a review showing 60–120 mg/day reduced leg pain, heaviness, and swelling versus placebo.

Grape seed extract (from Vitis vinifera) contains OPCs and proanthocyanidins with clinical evidence for CVI and varicose vein-related symptoms. A 2001 double-blind, placebo-controlled RCT found grape seed proanthocyanidin extract significantly improved CVI symptoms. ConsumerLab cites several small studies showing it reduces venous insufficiency symptoms including leg swelling. Grape seed OPCs are mechanistically identical to pine bark procyanidins in their collagen-stabilizing and anti-inflammatory venous effects.

GSE has the strongest evidence base of any botanical for varicose veins. The 2025 VICTORY RCT (n=176) showed GSE significantly reduced venous reflux time in both superficial and deep veins versus controls. Meta-analyses also confirm symptom improvements including reduced leg heaviness, swelling, and pain in chronic venous insufficiency.

Hesperidin is a citrus flavanone glycoside used in combination with diosmin (as MPFF) as a first-line venoactive treatment for chronic venous disease including varicose veins. The combination diosmin-hesperidin has been shown in RCTs and meta-analyses to reduce limb swelling and improve quality of life versus placebo in CVI. Hesperidin alone and in combination contributes to venous tone improvement, reduced capillary permeability, and anti-inflammatory effects in the venous system.

Horse chestnut seed extract (HCSE), standardized to the saponin aescin, has strong clinical evidence for relieving symptoms of chronic venous insufficiency (CVI) associated with varicose veins. A Cochrane review of 17 RCTs (n≈1,580) found it reduced ankle swelling and leg pain comparably to compression stockings. Germany's Commission E and ESCOP have formally approved it for CVI. Five clinical studies including one trial in varicose vein patients demonstrated efficacy for lower leg edema and subjective symptoms.

Nattokinase is a fibrinolytic enzyme derived from fermented soybeans (natto) with clinical evidence for CVI and varicose vein-associated venous disease. An observational study of 153 CVI/thrombosis patients found complete symptom resolution after 30 days of nattokinase post-initial therapy. When combined with Pycnogenol, it reduced travel-associated clot risk in an RCT of 186 high-risk subjects. Life Extension's clinical protocol includes nattokinase for chronic venous disease management.

Oligomeric proanthocyanidins (OPCs) from grape seed and pine bark are the best-documented class of plant bioflavonoids for varicose veins and CVI. Placebo-controlled double-blind studies involving approximately 400 participants found OPCs provide significant benefits for varicose vein symptoms. OPCs improve collagen integrity, reduce capillary leakage, and control inflammation. ConsumerLab notes several small studies showing grape seed OPCs reduce symptoms of venous insufficiency.

Multiple RCTs and an ex vivo study show Pycnogenol (pine bark extract, 100–150 mg/day) improves venous tone, reduces varicose vein distensibility, and relieves chronic venous insufficiency symptoms. Pycnogenol was found more effective than compression stockings alone for CVI parameters in a 98-subject controlled study.

Pine bark extract (standardized as Pycnogenol from French maritime pine, Pinus pinaster) has clinical evidence from multiple RCTs for reducing CVI symptoms and varicose vein-related edema. In a 98-subject RCT, 150 mg/day for 8 weeks significantly reduced ankle swelling, resting skin flux, and CVI symptom scores, outperforming diosmin-hesperidin. It has been shown to improve venous tone in varicose vein segments and slow progression of varicose veins. Multiple clinical studies support 100–150 mg/day for CVI.

Proanthocyanidins are the class of polyphenol compounds in grape seed and pine bark principally responsible for their venous effects. They strengthen capillary walls, reduce permeability, and exert anti-inflammatory effects relevant to varicose veins and CVI. The evidence base, shared with Oligomeric proanthocyanidins and Pycnogenol, includes multiple double-blind placebo-controlled clinical studies in CVI and varicose vein patients showing significant symptomatic benefit.

Procyanidins are a subclass of proanthocyanidins (B-type catechin/epicatechin dimers and oligomers) present in Pycnogenol, grape seed, and other plant extracts studied for CVI and varicose veins. Pycnogenol is standardized to 70% procyanidins and has been shown in multiple RCTs to reduce CVI edema, improve venous tone in varicose vein segments, and slow varicose vein progression. Their mechanism includes collagen stabilization, anti-inflammatory effects, and reduction of capillary permeability.

Procyanidol (also referred to as procyanidin/OPC) is the class of condensed tannin flavonoids found in grape seed and pine bark that has been studied for varicose veins and CVI. As a component class of Pycnogenol and grape seed extracts, procyanidols underlie the clinical evidence of these preparations for CVI, reducing capillary leakage, strengthening vessel walls, and improving venous tone in placebo-controlled trials.

Pycnogenol is the standardized French maritime pine bark extract (Pinus pinaster) with robust clinical evidence for CVI and varicose veins. Multiple RCTs show it reduces leg edema, improves venous tone, and outperforms diosmin-hesperidin and grape leaf extract for CVI symptom relief. A 98-subject RCT found 150 mg/day for 8 weeks significantly reduced ankle swelling and CVI scores. A meta-analysis showed a mean difference of 25.30 in pain reduction vs. standard therapy. It also slows varicose vein progression and promotes venous ulcer healing.

Ruscogenins (ruscogenin and neoruscogenin) are the steroidal saponin constituents of Butcher's Broom (Ruscus aculeatus) responsible for its venotonic effects in chronic venous insufficiency and varicose veins. They induce venous wall contraction through adrenergic receptor activation, inhibit endothelial inflammation (TNF-alpha-induced ICAM-1), and demonstrate anti-elastase activity. ESCOP specifies 7–11 mg ruscogenins/day for CVI treatment.

Rutin is a naturally occurring flavonoid glycoside found in buckwheat, citrus, and other plants, used traditionally and in modern phytomedicine for varicose veins and CVI. Two double-blind, placebo-controlled studies found buckwheat tea (high in rutin) effective against varicose veins. Rutin and its derivatives (oxerutins/rutosides) have been shown in multiple controlled trials to reduce leg swelling, heaviness, and discomfort in CVI. It acts by strengthening capillaries, reducing capillary permeability and fragility, and inhibiting pro-inflammatory signaling.

Rutosides are a class of flavonoid glycosides derived from rutin, comprising the oxerutins (hydroxyethylrutoside mixture) used extensively in Europe for varicose veins and CVI. Multiple double-blind, placebo-controlled trials support their use, and they are covered by the 2020 Cochrane review on phlebotonics for venous insufficiency. They reduce leg aching, swelling, and fatigue, and have been shown effective for pregnancy-related varicosities.

Hydroxyethylrutosides (oxerutins), semisynthetic derivatives of rutin from S. japonica, have been used clinically in the treatment of varicose veins and chronic venous disorders. Rutin strengthens capillary walls and reduces venous permeability, providing pharmacological rationale for this application.

Troxerutin is a semisynthetic derivative of rutin (a hydroxyethylrutoside) used in Europe as a venoactive drug for varicose veins and CVI. It is one component of the standardized oxerutin mixture approved for venous insufficiency. There is evidence from double-blind, placebo-controlled clinical studies that it improves leg aching, swelling, and fatigue in varicose veins, and Cochrane-registered studies document its use in varicose vein patients. EBSCO Research Starters confirms it may be effective when taken alone at 600–1,200 mg/day.

Topical use of alkanet root preparations for varicose veins is a well-documented traditional indication in European and Mediterranean herbal medicine, with the root described as antibacterial, antipruritic, astringent, and vulnerary. It has also been combined with Pistacia atlantica resin, olive oil, and laurel for treating leg blood clots in traditional Bedouin medicine.

External application of a bayberry decoction as a wash or compress for varicose veins is a documented traditional use. Contemporary herbalists recommend it alongside hemorrhoids as a topical astringent. No clinical research supports this use.

Bromelain is a proteolytic enzyme complex from pineapple with antiedema effects similar to those used for varicose veins, supporting its proposed use. EBSCO Research Starters lists it as an 'other proposed natural treatment' for varicose veins, noting its antiedema properties and use in inflammation and tissue swelling. No direct clinical evidence exists for varicose veins specifically, but its mechanisms (fibrinolysis, anti-inflammation, edema reduction) align with CVI pathophysiology.

Calendula infusion applied externally as a compress or wash to varicose veins is documented in multiple ethnobotanical sources. The plant is traditionally used to improve vascular tone and reduce venous inflammation. No clinical trials for varicose veins have been conducted.

Varicose veins is a consistently listed traditional indication for Clematis in European and East Asian folk medicine, appearing in authoritative herbal reference monographs (RxList, ScienceDirect reviews citing Gruenwald et al., 2000). No clinical or experimental pharmacological studies have addressed this specific indication.

Collinsonia (Stone Root, Collinsonia canadensis) has a long history in North American herbal medicine as an oral treatment for varicose veins and hemorrhoids. EBSCO Research Starters acknowledges this traditional use while noting it has not been meaningfully scientifically evaluated. It was used by Eclectic physicians in the 19th century for venous congestion, portal hypertension, and varicose conditions.

Topical comfrey preparations have been used traditionally for varicose veins and thrombophlebitis in Western Europe, documented in historical herbals and Western herbal medicine texts. Practitioner survey data (n=239 herbalists, PubMed) confirm comfrey is used externally for varicose veins, though rated least effective for this indication. Rosmarinic acid and tannins may contribute anti-inflammatory and astringent effects relevant to venous inflammation.

Geranium has traditional use for varicose veins and phlebitis, attributed to its hemostatic, circulatory-stimulating, and astringent properties. Multiple herbal sources list this indication. No clinical trials have been conducted.

H. italicum EO is a traditional aromatherapy remedy for varicose veins, cited in multiple practitioner references for its circulatory and anti-edema properties. No clinical trials on varicose veins with H. italicum exist; laboratory evidence is limited to anti-inflammatory and anti-edema mechanisms.

Varicose veins and varicose ulcers are listed as traditional indications in multiple prickly ash monographs, based on its classification as a circulatory stimulant that promotes peripheral blood flow. Eclectic physicians and naturopathic herbal texts record its use for this condition. No clinical trial evidence supports this use.

Shepherd's purse is traditionally used both internally and topically for varicose veins, documented by Herbal Reality as stimulating circulation and supporting venous system integrity. Its flavonoid content (particularly rutin and diosmin) provides a mechanistic rationale for capillary and venous wall support. WebMD lists varicose veins as a use with insufficient evidence for efficacy rating.

Sweet Clover (Melilotus officinalis) has been used in European phytomedicine for CVI, varicose veins, and associated edema, and Germany's Commission E has approved its use for venous insufficiency. It contains coumarin and related compounds with venotonic and anti-inflammatory effects. Its traditional and regulatory recognition predates comprehensive RCT evidence, though pharmacological studies support its mechanism.

White oak bark is traditionally used topically as a compress or wash for varicose veins to tone and tighten venous tissue. Its astringent action on blood vessel walls is the proposed mechanism. No clinical trials exist; the use is documented in herbalism and supported by Commission E's acknowledgment of venous-related indications.

Witch Hazel (Hamamelis virginiana) has a long traditional use in North American and European folk medicine as a topical astringent for varicose veins, hemorrhoids, and venous swelling. Its tannin content is thought to constrict blood vessels and reduce local inflammation. EBSCO Research Starters lists it as an 'other proposed natural treatment' for varicose veins. Modern scientific evidence for its efficacy specifically in venous insufficiency is limited, with studies primarily documenting its anti-inflammatory and astringent topical effects.

Wood betony is documented in European folk herbalism as a remedy for varicose veins, both internally and topically. The PeaceHealth health library lists this use explicitly. Tannin content provides a proposed mechanistic basis via venous toning.

Traditional Chinese medicine and European folk medicine have used yarrow for varicose veins, linked to its venotonic and vasoprotective properties. A standardized extract has demonstrated vasoprotective activity in preclinical research.